Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials

Trial Profile

Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Cladribine (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PREMIERE
  • Sponsors EMD Serono; Merck Serono
  • Most Recent Events

    • 28 Oct 2017 Results of post hoc integrated safety analysis of CLARITY, CLARITY EXTENSION, ORACLE-MS and PREMIERE trials assessing the infectious adverse events occurring during exact periods of Grade 3 or 4 lymphopenia presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 28 Oct 2017 Results (n=685) of pooled data from CLARITY, CLARITY Extension and PREMIERE studies assessing absolute lymphocyte count, presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis.
    • 28 Oct 2017 Results of malignancy risk data from three phase III studies and PREMIERE registry presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top